Last updated on February 2020

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Brief description of study

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Clinical Study Identifier: NCT03343613

Find a site near you

Start Over

Gustave Roussy

Villejuif Cedex, France
  Connect »